GLP-1 & compounded medication availability in Hawaii (2026)
Every prescription that reaches Hawaii from a mainland pharmacy arrives the way the rest of the islands’ mail does, by air, and the state writes its pharmacy rules accordingly, with an explicit permit requirement for out-of-state pharmacies shipping in. OrderlyMeds serves Hawaii addresses on our standard national terms. This page lays out all ten product lines we track: what ships, what does not, and what Hawaii’s pharmacy regulators actually say.
What ships to Hawaii: all ten lines
| Product line | Available in Hawaii? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Ships to Hawaii addresses; the published window is national. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | National pricing applies in Hawaii at every dose. |
| NAD+ | Yes | 8–10 business days | Same signup flow as the weight-care lines. |
| Sermorelin | Yes | 8–10 business days | Ships by mail from licensed partner pharmacies. |
| Glutathione | No | N/A | Not something OrderlyMeds offers today. |
| BPC-157 | Yes | 8–10 business days | Carried as an injectable; read its federal record below. |
| TB-500 | Yes | 8–10 business days | Carried as an injectable, with its own section below. |
| KPV | No | N/A | We do not carry it; these lines are compounded as injectables only. |
| Epitalon | Yes | 8–10 business days | Carried as an injectable; the federal picture is below. |
| MOTS-c | Yes | 8–10 business days | Carried as an injectable, with a federal record all its own, below. |
Rows marked “No” stay on the page on purpose; omitting them would be the dishonest version. Hawaii facts last reviewed November 16, 2026.
Research peptides in Hawaii: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Four of the five ship to Hawaii addresses: BPC-157, TB-500, Epitalon and MOTS-c, all compounded injectables filled on patient-specific prescriptions. KPV does not, because it is not an injectable line and injectables are what we compound. Each section below carries that substance’s own federal record, stated whether the line ships to you or not; no two of the five share quite the same one.
BPC-157 in Hawaii
Ships to Hawaii addresses as a compounded injectable, filled on a patient-specific prescription. Both federal facts below apply.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Hawaii
Part of the Hawaii offering as a compounded injectable under a patient-specific prescription. Its record follows.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Hawaii
Not dispensed to Hawaii, or any state. Injectables are what we compound, and KPV is not one.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Hawaii
Available for Hawaii as a compounded injectable on a patient-specific prescription; the federal picture below is unaffected.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Hawaii
Ships to Hawaii as a compounded injectable on a patient-specific prescription. Its federal record is not the others’, so read it on its own.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Hawaii’s pharmacy regulators say about compounded medications
Hawaii regulates inbound pharmacy the way you would expect of a state every mainland package must fly to: through permits. The pharmacy chapter of state law reaches out-of-state pharmacies explicitly, and the state’s telehealth law is equally explicit that care can begin online. For a Hawaii patient, the questions that matter are the pharmacy’s Hawaii permit, the prescriber’s Hawaii license, and a prescription written for you specifically.
Hawaii law makes it unlawful for an out-of-state pharmacy to distribute, ship, mail, or deliver prescription drugs into the state without first obtaining a permit from the board (HRS § 461-15); the board administers this as its miscellaneous permit for out-of-state pharmacies. Source: Hawaii Revised Statutes, ch. 461 (Pharmacists and Pharmacy) · Hawaii Board of Pharmacy — miscellaneous permit instructions.
Pharmacy practice and compounding in Hawaii are governed by HRS chapter 461 and the board’s administrative rules (Title 16, chapter 95); no GLP-1-specific or peptide-specific prohibition has been published by the board. Source: Hawaii Board of Pharmacy.
A physician-patient relationship may be established via telehealth by a Hawaii-licensed physician, and prescriptions issued in such encounters are held to the same standard of appropriate practice as in-person care (HRS § 453-1.3); an in-person consultation is required only for categories such as opiate prescribing and medical cannabis certification — not the medications on this page. Source: Hawaii State Legislature — HRS § 453-1.3.
A Hawaii order follows the same sequence as a mainland one: eligibility check, telehealth evaluation with a Hawaii-licensed provider, fulfillment by a permitted partner pharmacy, air-mail delivery to your address. National pricing applies unchanged in Hawaii, at every dose.
Hawaii availability FAQs
Is compounded semaglutide available in Hawaii?
Yes. OrderlyMeds ships compounded semaglutide to Hawaii addresses at the same national price as every other state, $74/month for the first two months for new customers.
Is delivery to Hawaii slower than the mainland?
Our published window is 8–10 business days from signup nationwide; we do not publish a separate Hawaii window.
Do I need an in-person doctor visit to start in Hawaii?
No. Hawaii's rules on this are cited in the regulator section above. A telehealth evaluation with a Hawaii-licensed provider is how an order starts.
Can I get BPC-157 or other research peptides shipped to Hawaii?
Four of the five ship as compounded injectables on patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not. Each line's own federal record is above.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
